

**Olanzapine (Zyprexa<sup>®</sup>)**

**No. 98/04**

**Eli Lilly and Company Ltd**

## Summary of Recommendation

10 May, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**Advice:** following a full submission.

Olanzapine (Zyprexa<sup>®</sup>) is accepted for use within NHS Scotland for the prevention of recurrence in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.

Olanzapine has been shown to be significantly superior to placebo in delaying symptomatic relapse of mania or depression and of mania alone. Apart from weight gain, somnolence and treatment-emergent depression, most significant differences between olanzapine and active competitors favoured olanzapine.

Professor David H Lawson  
Chairman